Skip to main content
Top
Published in: Infection 6/2011

01-12-2011 | Images in infection

Bullae and purpura revealing protein C consumption

Authors: M. Piastra, I. Bersani, D. Pietrini, M. P. de Carolis, G. Conti, F. Vitale, P. Valentini

Published in: Infection | Issue 6/2011

Login to get access

Excerpt

We present two patients’ clinical images showing severe foot lesions characterized by bullous appearance over a diffusely purpuric skin, with serious fingertip involvement. Figure 1a and b presents a 4-year-old child suffering from Streptococcus pyogenes septic shock while Fig. 1c and d shows an 18-month-old child with group C Neisseria meningitidis septic shock. Both cases were complicated by severe DIC (with admission protein C level equal to 8 and 2%, respectively) followed by massive rhabdomyolysis and myoglobinuria; low-dose fenoldopam maintained renal function in the first case, whereas hemodiafiltration was necessary in the second patient. Both children survived after receiving high-level hemodynamic and ventilatory support.
Literature
2.
go back to reference Fretzayas A, Douros K, Moustaki M, Nicolaidou P. Papular-purpuric gloves and socks syndrome in children and adolescents. Pediatr Infect Dis J. 2009;28:250–2.PubMedCrossRef Fretzayas A, Douros K, Moustaki M, Nicolaidou P. Papular-purpuric gloves and socks syndrome in children and adolescents. Pediatr Infect Dis J. 2009;28:250–2.PubMedCrossRef
3.
go back to reference Buysse CM, Oranje AP, Zuidema E, Hazelzet JA, Hop WC, Diepstraten AF, Joosten KF. Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child. 2009;94:381–6.PubMedCrossRef Buysse CM, Oranje AP, Zuidema E, Hazelzet JA, Hop WC, Diepstraten AF, Joosten KF. Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child. 2009;94:381–6.PubMedCrossRef
4.
go back to reference Dhodapkar K, Corbacioglu S, Chang MW, Karpatkin M, DiMichele D. Purpura fulminans caused by group A beta-hemolytic Streptococcus sepsis. J Pediatr. 2000;137:562–7.PubMedCrossRef Dhodapkar K, Corbacioglu S, Chang MW, Karpatkin M, DiMichele D. Purpura fulminans caused by group A beta-hemolytic Streptococcus sepsis. J Pediatr. 2000;137:562–7.PubMedCrossRef
5.
go back to reference de Kleijn ED, de Groot R, Hack CE, Mulder PG, Engl W, Moritz B, Joosten KF, Hazelzet JA. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med. 2003;31:183918–47. de Kleijn ED, de Groot R, Hack CE, Mulder PG, Engl W, Moritz B, Joosten KF, Hazelzet JA. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med. 2003;31:183918–47.
Metadata
Title
Bullae and purpura revealing protein C consumption
Authors
M. Piastra
I. Bersani
D. Pietrini
M. P. de Carolis
G. Conti
F. Vitale
P. Valentini
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Infection / Issue 6/2011
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-011-0150-4

Other articles of this Issue 6/2011

Infection 6/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine